Francesca Musumeci
Overview
Explore the profile of Francesca Musumeci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Maria S, Passannanti R, Poggialini F, Vagaggini C, Serafinelli A, Bianchi E, et al.
Eur J Med Chem
. 2025 Jan;
286:117285.
PMID: 39884903
No abstract available.
2.
Di Maria S, Passannanti R, Poggialini F, Vagaggini C, Serafinelli A, Bianchi E, et al.
Eur J Med Chem
. 2024 Oct;
280:116929.
PMID: 39406114
Hepatocellular carcinoma (HCC) is the most common type of liver solid tumor and the second leading cause of cancer-related deaths worldwide. Although new treatment options have been recently approved, the...
3.
Giacchello I, Cianciusi A, Bertagnin C, Bonomini A, Francesconi V, Mori M, et al.
Pharmaceutics
. 2024 Jul;
16(7).
PMID: 39065650
The limited range of available flu treatments due to virus mutations and drug resistance have prompted the search for new therapies. RNA-dependent RNA polymerase (RdRp) is a heterotrimeric complex of...
4.
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy
Musumeci F, Schenone S
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794286
Kinases are a family of enzymes comprising over five hundred members, which, when overexpressed or hyperactivated, are implicated in the pathogenesis of numerous hematological and solid cancers [...].
5.
Scarano N, Brullo C, Musumeci F, Millo E, Bruzzone S, Schenone S, et al.
Pharmaceuticals (Basel)
. 2024 May;
17(5).
PMID: 38794171
Sirtuins (SIRTs) are classified as class III histone deacetylases (HDACs), a family of enzymes that catalyze the removal of acetyl groups from the ε-N-acetyl lysine residues of histone proteins, thus...
6.
Grossi G, Scarano N, Musumeci F, Tonelli M, Kanov E, Carbone A, et al.
Molecules
. 2024 Apr;
29(8).
PMID: 38675561
The search for novel effective TAAR1 ligands continues to draw great attention due to the wide range of pharmacological applications related to TAAR1 targeting. Herein, molecular docking studies of known...
7.
Vagaggini C, Petroni D, DAgostino I, Poggialini F, Cavallini C, Cianciusi A, et al.
Drug Dev Res
. 2024 Feb;
85(1):e22158.
PMID: 38349262
Glioblastoma multiforme (GBM) is one of the most aggressive malignancies with a high recurrence rate and poor prognosis. Theranostic, combining therapeutic and diagnostic approaches, arises as a successful strategy to...
8.
Frumento D, Grossi G, Falesiedi M, Musumeci F, Carbone A, Schenone S
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338677
In the last decade, many small molecules, usually characterized by heterocyclic scaffolds, have been designed and synthesized as tyrosine kinase inhibitors (TKIs). Among them, several compounds have been tested at...
9.
Scarano N, Di Palma F, Origlia N, Musumeci F, Schenone S, Spinelli S, et al.
Pharmaceutics
. 2023 Dec;
15(12).
PMID: 38140095
The lanthionine synthetase C-like (LANCL) proteins include LANCL2, which is expressed in the central nervous system (CNS) and in peripheral tissues. LANCL2 exhibits glutathionylation activity and is involved in the...
10.
Poggialini F, Vagaggini C, Brai A, Pasqualini C, Carbone A, Musumeci F, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004393
Although patients would rather oral therapies to injections, the gastrointestinal tract's low permeability makes this method limiting for most compounds, including anticancer drugs. Due to their low bioavailability, oral antitumor...